Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma
Completed
Eli Lilly and Company
Phase 2
2000-07-01
Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation
and be more effective clinically in non-small cell lung cancer
Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma
Completed
National University Hospital, Singapore
Phase 2
2000-07-01
Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation
and be more effective clinically in non-small cell lung cancer
This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs.
intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic
cystoid macular edema (CME). Twenty consented patients with acute CME after
phacoemulsification cataract surgery with posterior chamber intraocular lens implantation
(PE/PCIOL) will be randomized 1:1 to treatment with R or T. R patients will receive three
monthly R injections, followed by PRN dosing. T patients will receive PRN injections every 3
months. Clinical CME is defined as clinically evident CME, with visual acuity (VA) typically
in the 20/40 to 20/200 range. Re-treatment criteria will include clinically evident worsening
of CME, combined with any of the following:
- Any increase in spectral domain ocular coherence tomography (OCT) central macular
thickness (CMT)
- Any observable fluid on OCT
- Any qualitatively increased perifoveal leakage/pooling on fluorescein angiography (FA).
Patients will be followed monthly through 12 months.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.